Screener
Nurix Therapeutics, Inc. NRIX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | May 31,2026 | November 30,2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 43,267 | 54,852 |
| Operating lease liabilities, current | 3,221 | 2,824 |
| Deferred revenue, current | 13,324 | 17,580 |
| Total current liabilities | 72,020 | 86,471 |
| Operating lease liabilities, net of current portion | 54,922 | 52,906 |
| Deferred revenue, net of current portion | 5,971 | 10,011 |
| Total liabilities | 132,913 | 149,388 |
| Commitments and contingencies (Note 6) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s total current liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported total current liabilities of $72.02M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s total current liabilities decreased by 4.8% year-over-year, from $75.61M to $72.02M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s total current liabilities has grown at a 14.2% compound annual growth rate (CAGR), from $44.54M to $86.47M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Nurix Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude